IL149402A0 - Arylamine derivatives and their use as anti-telomerase agent - Google Patents

Arylamine derivatives and their use as anti-telomerase agent

Info

Publication number
IL149402A0
IL149402A0 IL14940200A IL14940200A IL149402A0 IL 149402 A0 IL149402 A0 IL 149402A0 IL 14940200 A IL14940200 A IL 14940200A IL 14940200 A IL14940200 A IL 14940200A IL 149402 A0 IL149402 A0 IL 149402A0
Authority
IL
Israel
Prior art keywords
arylamine derivatives
telomerase agent
telomerase
agent
concerns
Prior art date
Application number
IL14940200A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9915031A external-priority patent/FR2801588B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL149402A0 publication Critical patent/IL149402A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14940200A 1999-11-29 2000-11-27 Arylamine derivatives and their use as anti-telomerase agent IL149402A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9915031A FR2801588B1 (fr) 1999-11-29 1999-11-29 Derives chimiques et leur application comme agent antitelomerase
FR0010561 2000-08-11
PCT/FR2000/003310 WO2001040218A1 (fr) 1999-11-29 2000-11-27 Derives arylamines et leur application comme agent antitelomerase

Publications (1)

Publication Number Publication Date
IL149402A0 true IL149402A0 (en) 2002-11-10

Family

ID=26212577

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14940200A IL149402A0 (en) 1999-11-29 2000-11-27 Arylamine derivatives and their use as anti-telomerase agent

Country Status (27)

Country Link
EP (1) EP1244650B1 (et)
JP (1) JP2003515604A (et)
KR (1) KR20020058043A (et)
CN (1) CN1402722A (et)
AT (1) ATE243692T1 (et)
AU (1) AU2179001A (et)
BG (1) BG106753A (et)
BR (1) BR0015992A (et)
CA (1) CA2392507A1 (et)
CO (1) CO5251431A1 (et)
CZ (1) CZ20021849A3 (et)
DE (1) DE60003583T2 (et)
DK (1) DK1244650T3 (et)
EA (1) EA200200616A1 (et)
EE (1) EE200200263A (et)
ES (1) ES2202206T3 (et)
HU (1) HUP0204429A2 (et)
IL (1) IL149402A0 (et)
MX (1) MXPA02005276A (et)
NO (1) NO20022528D0 (et)
PE (1) PE20010912A1 (et)
PL (1) PL355667A1 (et)
PT (1) PT1244650E (et)
SK (1) SK7402002A3 (et)
UY (1) UY26456A1 (et)
WO (1) WO2001040218A1 (et)
YU (1) YU38102A (et)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
AU2001228638A1 (en) 2000-01-28 2001-08-07 Astrazeneca Ab Chemical compounds
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
AU2001282268A1 (en) * 2000-08-08 2002-02-18 Aventis Pharma S.A. Phenantridine derivatives and their use as anti-telomerase agent
NZ526542A (en) 2000-12-21 2005-01-28 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators
FR2821355A1 (fr) * 2001-02-23 2002-08-30 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
CO5380035A1 (es) * 2001-03-23 2004-03-31 Aventis Pharma Sa Derivados quimicos y su aplicacion como agente antitelomerasa
FR2822468B1 (fr) * 2001-03-23 2008-06-20 Aventis Pharma Sa Derives chimiques et leur application comme agent anti-telomerase
JP2004534046A (ja) * 2001-05-28 2004-11-11 アベンティス・ファーマ・ソシエテ・アノニム 化学誘導体および抗テロメラーゼ剤としてのその使用
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
CA2498281A1 (en) * 2002-09-10 2004-03-25 Pharmacia Italia S.P.A. Substituted pyridine derivatives as antitumor agent
AU2003275726A1 (en) * 2002-10-24 2004-05-13 Chong Kun Dang Pharmaceutical Corp. 2 - substituted heterocyclic compounds and antitumor composition comprising the same
FR2850970B1 (fr) * 2003-02-07 2006-07-07 Aventis Pharma Sa Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
JP4691041B2 (ja) * 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
JP5548363B2 (ja) 2005-10-28 2014-07-16 アルマック サイエンシーズ （スコットランド） リミテッド 新規な蛍光染料およびその使用
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
KR100761869B1 (ko) * 2006-07-07 2007-10-04 김현기 트리아진 유도체 화합물 및 이를 포함하는 암 치료용조성물
EP2441757A1 (en) * 2006-07-31 2012-04-18 Praecis Pharmaceuticals Incorporated Aurora kinase inhibitors from an encoded small molecule library
JP5325517B2 (ja) * 2007-10-12 2013-10-23 住友化学株式会社 ジベンゾオキセピン化合物の精製方法
JP2009102249A (ja) * 2007-10-22 2009-05-14 Sumitomo Chemical Co Ltd ジベンゾオキセピン化合物の結晶の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
US5770613A (en) * 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
JPH1160573A (ja) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd トリアジン誘導体及びテロメラーゼ阻害剤
DE69909246D1 (de) * 1998-02-04 2003-08-07 Univ Texas Hemmung der menschlichen telomerase durch g-quadruplex interaktionverbindung
DE19812879A1 (de) * 1998-03-24 1999-09-30 Bayer Ag Substituierte 2,4-Diamino-1,3,5-triazine

Also Published As

Publication number Publication date
JP2003515604A (ja) 2003-05-07
MXPA02005276A (es) 2002-11-07
BR0015992A (pt) 2002-08-06
EP1244650B1 (fr) 2003-06-25
EP1244650A1 (fr) 2002-10-02
EE200200263A (et) 2003-06-16
YU38102A (sh) 2004-12-31
DE60003583T2 (de) 2004-05-13
DE60003583D1 (de) 2003-07-31
AU2179001A (en) 2001-06-12
CA2392507A1 (fr) 2001-06-07
UY26456A1 (es) 2001-06-29
PE20010912A1 (es) 2001-09-01
PL355667A1 (en) 2004-05-04
ATE243692T1 (de) 2003-07-15
PT1244650E (pt) 2003-11-28
BG106753A (bg) 2003-02-28
DK1244650T3 (da) 2003-10-20
SK7402002A3 (en) 2002-11-06
CZ20021849A3 (cs) 2002-08-14
CO5251431A1 (es) 2003-02-28
KR20020058043A (ko) 2002-07-12
EA200200616A1 (ru) 2002-10-31
NO20022528L (no) 2002-05-28
CN1402722A (zh) 2003-03-12
WO2001040218A1 (fr) 2001-06-07
HUP0204429A2 (hu) 2003-04-28
NO20022528D0 (no) 2002-05-28
ES2202206T3 (es) 2004-04-01

Similar Documents

Publication Publication Date Title
IL149402A0 (en) Arylamine derivatives and their use as anti-telomerase agent
DE60112974D1 (en) Carbolinderivate
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
WO2002096903A3 (fr) Derives chimiques et leur application comme agent antitelomerase
EP1311262A4 (en) COMBINED TREATMENT AGAINST CANCER
DE60216233D1 (en) Carbolinderivate
MXPA06000247A (es) Tetrahidro-1h-pirazolo[3,4-c]piridinas sustituidas composiciones que las contienen y su utilizacion.
GB9514473D0 (en) Chemical compounds
BG106586A (en) Pyrazolopyramidines as therapeutic agents
AU6048201A (en) Quinazoline derivatives for the treatment of tumours
MXPA03002911A (es) Compuestos quimicos.
ATE231872T1 (de) Thiazolopyrimidinderivate
HK1076812A1 (en) Cyanoguanidine prodrugs
MXPA02012076A (es) Compuestos quimicos.
MXPA02012659A (es) Derivados de pirazindiona condensados.
IL159887A0 (en) Combination therapy for the treatment of cancer
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
MXPA03002909A (es) Compuestos quimicos.
GB0018951D0 (en) Novel compounds
GB0027705D0 (en) Novel compounds
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
MXPA02012472A (es) Compuestos quimicos.
HK1050533A1 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer.
RS47804A (en) 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof
ZA200408071B (en) Combination therapy for the treatment of cancer.